A Potent Cell Death Activity Associated with Transient High Level Expression of BCL-2*

The BCL-2 proto-oncogene contains unusually long untranslated 5′ and 3′ sequences. Deletion of the sequences flanking the BCL-2 open reading frame dramatically increases the level of protein expression. Transient high level BCL-2 protein expression mediated by plasmid transfection or by infection with recombinant adenovirus results in potent apoptosis of several cell lines. Detailed mutational (deletion and add-back) analysis reveals that both 5′- and 3′-flanking sequences contribute to the negative modulation of protein expression from the BCL-2 open reading frame. It appears that these sequences exert the negative regulatory effect in an orientation-dependent manner. Analysis of BCL-2RNA levels indicate that elevated levels of mRNA may be the primary cause of elevated levels of protein expression. Apoptosis induced by adenovirus vectors expressing elevated levels of BCL-2 can be readily inhibited by the caspase inhibitor z-VAD-fmk, suggesting that high levels of BCL-2 expression induce apoptosis via the caspase cascade. Mutational analysis of BCL-2 indicates that its pro-apoptotic activity is separable from its anti-apoptosis activity. Our results raise the possibility that oncogenic conversion of BCL-2 may require somatic mutations in the pro-apoptotic activity, in addition to other activating mutations that result in enhanced expression. Consistent with this hypothesis, a somatic mutation of BCL-2 observed in multiple human tumors results in reduced apoptosis activity.

[1]  G Waksman,et al.  Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Hengartner.  Apoptosis CED-4 is a stranger no more , 1997, Nature.

[3]  D. Vaux,et al.  CED-4—The Third Horseman of Apoptosis , 1997, Cell.

[4]  S. Benchimol,et al.  Participation of the human p53 3′UTR in translational repression and activation following γ‐irradiation , 1997, The EMBO journal.

[5]  John Calvin Reed.  Double identity for proteins of the Bcl-2 family , 1997, Nature.

[6]  G. Evan,et al.  Cancer‐A matter of life and cell death , 1997, International journal of cancer.

[7]  John Calvin Reed,et al.  Bax accelerates staurosporine‐induced but suppresses nigericin‐induced neuronal cell death , 1997, Neuroreport.

[8]  J C Reed,et al.  Channel formation by antiapoptotic protein Bcl-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[10]  M. Cohen,et al.  Fas-mediated apoptosis in human prostatic carcinoma cell lines. , 1997, Cancer research.

[11]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[12]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[13]  G. Schneider,et al.  Bcl-2 promotes regeneration of severed axons in mammalian CNS , 1997, Nature.

[14]  A. Strasser,et al.  The cell death inhibitor Bcl‐2 and its homologues influence control of cell cycle entry. , 1996, The EMBO journal.

[15]  R. Warnke,et al.  Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. , 1996, Blood.

[16]  J. M. Adams,et al.  Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. , 1996, Oncogene.

[17]  N. Hay,et al.  Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. , 1996, Cancer research.

[18]  C. Borner.  Diminished Cell Proliferation Associated with the Death-protective Activity of Bcl-2* , 1996, The Journal of Biological Chemistry.

[19]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[20]  A. Chinnaiyan,et al.  The cell-death machine , 1996, Current Biology.

[21]  D. Green,et al.  Fas-mediated apoptosis and sphingomyelinase signal transduction: the role of ceramide as a second messenger for apoptosis. , 1996, Cell death and differentiation.

[22]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[23]  John Calvin Reed,et al.  A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. , 1996, Oncogene.

[24]  J. M. Boyd,et al.  Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. , 1995, Oncogene.

[25]  T. Chittenden,et al.  A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. , 1995, The EMBO journal.

[26]  Matthew J. Brauer,et al.  Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak , 1995, Nature.

[27]  G. Evan,et al.  Induction of apoptosis by the Bcl-2 homologue Bak , 1995, Nature.

[28]  G. Chinnadurai,et al.  p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Kinzler,et al.  Paradoxical inhibition of solid tumor cell growth by bcl2. , 1994, Cancer research.

[31]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[32]  H. Horvitz,et al.  Activation of C. elegans cell death protein CED-9 by an ammo-acid substitution in a domain conserved in Bcl-2 , 1994, Nature.

[33]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[34]  Junying Yuan,et al.  Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.

[35]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[36]  S. Korsmeyer,et al.  A negative regulatory element in the bcl-2 5'-untranslated region inhibits expression from an upstream promoter , 1993, Molecular and cellular biology.

[37]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[38]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[39]  M. Arens,et al.  Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[41]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[42]  S. Korsmeyer,et al.  Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma. , 1988, The EMBO journal.

[43]  M. Negrini,et al.  Molecular analysis of mbcl-2: Structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma , 1987, Cell.

[44]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[45]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[47]  John Calvin Reed,et al.  Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. , 1992, Blood.